Theramex, a dedicated Women’s Health Company and leading provider of Hormone Replacement Therapy (HRT), has been notified by the UK Department of Health and Social Care (DHSC), that shortages of some HRT therapies are anticipated. Additionally, a number are being discontinued. These products are transdermal patches which deliver HRT for oestrogen deficiency symptoms in peri and postmenopausal women.<\/p>\n\n\n\n
We aim to support the women and Healthcare Professionals (HCPs), who are affected by this. Accordingly, we have confirmed with the DHSC that we will take the following steps to ensure that women have access to an appropriate alternative product:<\/p>\n\n\n\n
\u2022 We are continuing to enable access to our existing stock of Evorel\u00ae, which will cover all shortages\/discontinuation in the short term<\/p>\n\n\n\n
\u2022 We are raising awareness with HCPs that Evorel\u00ae is a viable alternative which is available to women affected by the shortage\/discontinuation<\/p>\n\n\n\n
\u2022 We are monitoring the situation and will trigger plans to increase manufacturing if this is necessary to ensure longer term capacity.<\/p>\n\n\n\n
Theramex will continue to work with the DHSC and HCPs to ensure that affected women have easy access to an appropriate alternative therapy.<\/p>\n\n\n\n